Unveiling GSPT1 as a crucial prognostic biomarker and therapeutic vulnerability in breast cancer
- 1Department of Biological Sample Bank, The First Affiliated Hospital of Zhengzhou University
- 2Department of Breast Surgery, The First Affiliated Hospital of Zhengzhou University
- 3Department of Obstetrics and Gynecology, The First Affiliated Hospital of Zhengzhou University
Abstract
Breast cancer (BRCA) remains a leading cause of cancer-related mortality worldwide, necessitating the identification of novel biomarkers and therapeutic targets to overcome challenges such as treatment resistance and metastasis. In this study, we systematically characterized the multi-omic landscape of G1 to S phase transition protein 1 (GSPT1) in BRCA. Integrative bioinformatic analysis of public datasets revealed that GSPT1 mRNA and protein levels are significantly upregulated in BRCA across all clinical stages and molecular subtypes. To validate these findings, we performed immunohistochemical (IHC) staining on representative patient-derived tissue samples, which, complemented by transcriptomic analysis of diverse cell lines, confirmed this upregulation. High GSPT1 expression and its prevalent genomic alterations identified in public cohorts—particularly gene amplification observed in approximately 14% of cases—were strongly correlated with poor clinical outcomes, including diminished overall survival (OS), relapse-free survival (RFS), and distant metastasis-free survival (DMFS). Functional enrichment analyses indicated that GSPT1 expression is strongly associated with pathways critical for tumorigenesis, such as the cell cycle, DNA replication, and mitotic spindle organization. Furthermore, dependency analysis via the DepMap database and our experimental validation demonstrated that BRCA cells are highly dependent on GSPT1 for survival. Collectively, our findings further substantiate GSPT1 as a robust prognostic biomarker and provide translational evidence supporting its feasibility as a molecular glue-targetable vulnerability for precision oncology in BRCA.
Related
- ATG16L2 as a prognostic biomarker and therapeutic target in kidney renal clear cell carcinoma
- CHCHD2 as a prognostic biomarker and therapeutic target in lung adenocarcinoma: Insights from pan-cancer multi-omics and functional studies
- Disulfidptosis-related genes stratify molecular subtypes and highlight MYH9 as a prognostic biomarker and candidate therapeutic target in pancreatic ductal adenocarcinoma
- Comprehensive Pan-Cancer Bioinformatics Analysis Identifies DHX58 as a Promising Therapeutic Target and Prognostic Biomarker Across Multiple Tumor Types
- Life's Essential 8 and Life's Crucial 9 as Prognostic Indicators for Hip Fracture Outcomes: A Multicenter Prospective Cohort Study.
BibTeX
@article{wang2026unveiling,
title = {{Unveiling GSPT1 as a crucial prognostic biomarker and therapeutic vulnerability in breast cancer}},
author = {Huafei Wang and Chenxi Li and Zhu Zhu and Xinwei Liu and Shan Jiang and Li Wang and Yijuan Liu and Hanlin Fu and Ruixia Guo},
journal = {Scientific Reports},
year = {2026},
month = jul,
doi = {10.1038/s41598-026-61699-w},
url = {https://doi.org/10.1038/s41598-026-61699-w},
note = {CC BY},
}
RIS
TY - JOUR
TI - Unveiling GSPT1 as a crucial prognostic biomarker and therapeutic vulnerability in breast cancer
AU - Huafei Wang
AU - Chenxi Li
AU - Zhu Zhu
AU - Xinwei Liu
AU - Shan Jiang
AU - Li Wang
AU - Yijuan Liu
AU - Hanlin Fu
AU - Ruixia Guo
PY - 2026
DA - 2026/07/01
JO - Scientific Reports
DO - 10.1038/s41598-026-61699-w
UR - https://doi.org/10.1038/s41598-026-61699-w
AB - Breast cancer (BRCA) remains a leading cause of cancer-related mortality worldwide, necessitating the identification of novel biomarkers and therapeutic targets to overcome challenges such as treatment resistance and metastasis. In this study, we systematically characterized the multi-omic landscape of G1 to S phase transition protein 1 (GSPT1) in BRCA. Integrative bioinformatic analysis of public datasets revealed that GSPT1 mRNA and protein levels are significantly upregulated in BRCA across all clinical stages and molecular subtypes. To validate these findings, we performed immunohistochemical (IHC) staining on representative patient-derived tissue samples, which, complemented by transcriptomic analysis of diverse cell lines, confirmed this upregulation. High GSPT1 expression and its prevalent genomic alterations identified in public cohorts—particularly gene amplification observed in approximately 14% of cases—were strongly correlated with poor clinical outcomes, including diminished overall survival (OS), relapse-free survival (RFS), and distant metastasis-free survival (DMFS). Functional enrichment analyses indicated that GSPT1 expression is strongly associated with pathways critical for tumorigenesis, such as the cell cycle, DNA replication, and mitotic spindle organization. Furthermore, dependency analysis via the DepMap database and our experimental validation demonstrated that BRCA cells are highly dependent on GSPT1 for survival. Collectively, our findings further substantiate GSPT1 as a robust prognostic biomarker and provide translational evidence supporting its feasibility as a molecular glue-targetable vulnerability for precision oncology in BRCA.
SN - 2045-2322
ER -